2455519-86-3
2455519-86-3
Chemical Structure
Usnoflast
- CAS No.: 2455519-86-3
- Formula:C21H29N3O3S
- Molecular Weight:403.54
InChIKey: HAMGPBKPACGWND-ZOXUKVPXSA-N
SMILES: C[C@]1(N(CCC1)C)/C=C/S(NC(NC2=C3C(CCC3)=CC4=C2CCC4)=O)(=O)=O
Biological Activity: Usnoflast is the selective, orally active inhibitor for NLRP3 that blocks the release of IL-1β, and exhibits anti-inflammatory activity[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Usnoflast | 98.59% | Usnoflast is the selective, orally active inhibitor for NLRP3 that blocks the release of IL-1β, and exhibits anti-inflammatory activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sulofenur | Sulofenur (LY186641) is an orally active anti-tumor agent. Sulofenur induces gene expression through calcium ion-dependent pathways and some protein kinase-independent pathways, and its effect is particularly enhanced in H-ras mutant cells. Sulofenur exhibits significant activity in mouse solid tumor models and human tumor xenograft models. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AMG-8562 | 98.82% | AMG-8562 is a selective, orally active transient receptor potential vanilloid 1 (TRPV1) modulator that inhibits the activation of rat TRPV1 by Capsaicin (HY-10448), Anandamide (HY-10863) and N-arachidonyldopamine (HY-110018), with IC50 values of 1.75, 9.29 and 3.87 nM, respectively. AMG-8562 blocks capsaicin-induced activation, potentiates pH5-induced activation and has no effect on heat-induced activation of rat TRPV1, whereas it completely blocks capsaicin- and heat-induced activation and partially blocks pH5-induced activation of human TRPV1. AMG-8562 can be used in studies of TRPV1 activation patterns, hyperalgesia and pain-related research. |
||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Selnoflast | 99.46% | Selnoflast (RO7486967), formerly somalix/RG6418/IZD334, is an orally active, potent, selective and reversible small molecule NLRP3 inflammasome inhibitor. Selnoflast is a potent inhibitor of IL-1β release stimulated by NLRP3 activation in human Alzheimer's disease (AD) monocyte-derived macrophages. Selnoflast is promising for research of AD and systemic inflammatory diseases, such as ulcerative colitis and chronic obstructive pulmonary disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Selnoflast monopotassium | Selnoflast (RO7486967) monopotassium, formerly somalix/RG6418/IZD334 monopotassium, is an orally active, potent, selective and reversible small molecule NLRP3 inflammasome inhibitor. Selnoflast monopotassium is a potent inhibitor of IL-1β release stimulated by NLRP3 activation in human Alzheimer's disease (AD) monocyte-derived macrophages. Selnoflast monopotassium is promising for research of AD and systemic inflammatory diseases, such as ulcerative colitis and chronic obstructive pulmonary disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
NLRP3-IN-20 | NLRP3-IN-20 (compound 11) is an orally available inhibitor of the NLRP3 inflammasome with an IC50 of 25 nM for IL-1β secretion. NLRP3-IN-20 has excellent pharmacokinetic properties and demonstrated significant efficacy in models of non-alcoholic steatohepatitis, fatal septic shock, and colitis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ASP-2205 | ASP-2205 is a 5-HT2C receptor agonist (human 5-HT2C receptor, EC50=0.85 nM; rat 5-HT2C receptor, EC50=2.5 nM). ASP-2205 enhances the pudendal nerve-mediated urethral closure reflex through the 5-HT2C receptor, thereby preventing urinary incontinence. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
3',4'-Tetramethylene-α-pyrrolidinobutiophenone hydrochloride | 99.9% | 3',4'-Tetramethylene-α-pyrrolidinobutiophenone hydrochloride is structurally categorized as a drug derivative. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
3',4'-Trimethylene-α-pyrrolidinobutiophenone hydrochloride | 3',4'-Trimethylene-α-pyrrolidinobutiophenone hydrochloride is classified as a drug derivative. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
3',4'-Trimethylene-α-pyrrolidinovalerophenone hydrochloride | 3',4'-Trimethylene-α-pyrrolidinovalerophenone hydrochloride is structurally categorized as a drug derivative. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glyhexamide | Glyhexamide is an effective hypoglycemic agent in adult diabetics. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Sharma, et al. Novel substituted sulfonylurea derivatives as NLRP3 modulators and their preparation. World Intellectual Property Organization, WO2020148619 A1. 2020-07-23.
- [2]. Chatterjee A, et al., A novel selective NLRP3 inhibitor shows disease-modifying potential in animal models of Parkinson's disease. Brain Res. 2024 Nov 1;1842:149129. [Content Brief]
